Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8911924 | 0.93 | MAOA (0.75) | MAOAHTR2ATAAR1AKT2CYP2A6 | |
| SCHEMBL1579623 | 0.91 | MAOA (0.72) | MAOAHTR2ATAAR1AKT2CYP2A6 | |
| Hydrochloric Acid SCHEMBL11697432 | 0.91 | MAOA (0.72) | MAOAHTR2ATAAR1CYP2A6SMN1; SMN2 | |
| SCHEMBL15245000 | 0.91 | AKT2 (0.62) | MAOAHTR2ATAAR1AKT2CYP2A6 | |
| Hydrochloric Acid SCHEMBL7824070 | 0.90 | MAOA (0.69) | MAOAHTR2ATAAR1MAOBHDAC2 | |
| Putrescine SCHEMBL27220945 | 0.89 | HTR2A (0.65) | MAOAHTR2ATAAR1CYP2A6SMN1; SMN2 | |
| SCHEMBL172790 | 0.86 | TAAR1 (0.71) | HTR2ATAAR1CYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL52482 | 0.85 | MAOA (0.85) | MAOAHTR2ATAAR1CYP2A6SMN1; SMN2 | |
| SCHEMBL30869989 | 0.85 | HDAC2 (0.60) | MAOAHTR2ATAAR1MAOBFFAR1 | |
| Benzene SCHEMBL28170833 | 0.85 | MAOA (0.85) | MAOAHTR2ATAAR1CYP2A6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| CN-114981241-B | Novel compounds, process for their preparation and their use | 大邱庆北尖端医疗产业振兴财团 | 2024-11-19 | — | — | CN | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4065553-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-10-05 | — | — | EP | disclosed |
| CN-114981241-A | Novel compound, preparation method and application thereof | 大邱庆北尖端医疗产业振兴财团 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| CN-105142673-B | Novel cyclohexyl and quininuclidinyl carbamate derivatives with beta 2-adrenergic activator and M3 muscarinic antagonists activity | 阿尔米雷尔有限公司 | 2018-01-05 | — | — | CN | disclosed |
| WO-2016109501-A1 | AMIDE COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | KAROS PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2015089137-A1 | ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS | KAROS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010123599-A9 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2010123599-A2 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-10-28 | — | — | WO | disclosed |
| CN-100410236-C | Substituted methylene amide derivatives as protein tyrosine phosphatase modulators | APPLIED RESEARCH SYSTEMS (CH) | 2008-08-13 | — | — | CN | disclosed |
| CN-1633410-A | Substituted methylene amide derivatives as protein tyrosine phosphatase modulators | APPLIED RESEARCH SYSTEMS (AN) | 2005-06-29 | — | — | CN | disclosed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022024-A1 | ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS | CUTA, MMP8, CLPP | MAOA 3100/4885HTR2A 4739/4885TAAR1 4682/4885 |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | MAOA 239/4885HTR2A 532/4885TAAR1 78/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | MAOA 140/4885HTR2A 1526/4885TAAR1 386/4885 |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MAOA 2249/4885HTR2A 1489/4885TAAR1 3783/4885 |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | CASR, CALCR, ORAI1 | MAOA 4636/4885HTR2A 2770/4885TAAR1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.